Recent developments in cancer immunotherapy have introduced immune checkpoint inhibitors (ICIs) that target inhibitory receptors on T cells, such as PD-1 and CTLA-4, thus enhancing the immune system’s ability to eliminate cancer cells (11, 12). The gene discussed is CTLA4; the disease is cancer.